Arcutis Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Arcutis Biotherapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-22.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 59% of Healthcare companies in United States.
Cash Locked Ratio
$42For every $100 of sales, $42 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $194 tied up three years earlier.
More money tied up than 84% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$79Sales grew 10,103% in 3 years; of every extra $100 of sales, $79 became extra profit.
Higher than 77% of Healthcare companies in United States.
Asset Productivity Ratio
+10103% / -4%In 3 years sales changed by +10103% while total assets changed by -4%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-5.6×Operating cash was negative last year, while some debt falls due within a year.
Higher than 58% of Healthcare companies in United States.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Lower than 63% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 78% of Healthcare companies in United States.
Tangible Net Worth Ratio
92%Of every $100 of net worth, $92 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 75% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Arcutis Biotherapeutics, Inc. owes $0.55 for every $1 it owns. Arcutis Biotherapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
146.4Investors pay $146.4 for every $1 of Arcutis Biotherapeutics, Inc.'s yearly profit, higher than 94% of Healthcare companies in United States.
P/B ratio
18.35The share price is 18.35 times Arcutis Biotherapeutics, Inc.'s book value per share, higher than 93% of Healthcare companies in United States.
Market cap
$4.0 BThe total market value of all of Arcutis Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 82% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$221 MWhat Arcutis Biotherapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.75Net worth divided by the number of shares. The share price of $32.20 is 18.3 times this, which is the P/B above.
Return on equity (ROE)
15.9%Arcutis Biotherapeutics, Inc. earned 15.9% on its shareholders' money over the last year, higher than 87% of Healthcare companies in United States.
Owes vs Owns
0.55×Arcutis Biotherapeutics, Inc. owes $0.55 for every $1 it owns (moderate), higher than 60% of Healthcare companies in United States.
Dividend yield
NoneArcutis Biotherapeutics, Inc. does not currently pay a dividend.
Revenue growth
+91%Revenue rose 91% in the year to Dec 2025, and grew 367% a year on average over 3 years.
Profit growth
LossArcutis Biotherapeutics, Inc. made a loss in each of the last two years.
Profit margin
-4.3%Arcutis Biotherapeutics, Inc. lost $4 for every $100 of revenue.
Interest cover
Not coveredArcutis Biotherapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashArcutis Biotherapeutics, Inc. held $107 M more cash than debt (net cash) at Dec 2025.
Questions
What is Arcutis Biotherapeutics, Inc.'s P/E ratio?
Investors pay $146.4 for every $1 of Arcutis Biotherapeutics, Inc.'s yearly profit, higher than 94% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Arcutis Biotherapeutics, Inc.: $4.0 B ÷ $221 M (30 Jun 2026) = 18.3.
What is Arcutis Biotherapeutics, Inc.'s return on equity?
Arcutis Biotherapeutics, Inc. earned 15.9% on its shareholders' money over the last year, higher than 87% of Healthcare companies in United States.
How much does Arcutis Biotherapeutics, Inc. owe compared with what it owns?
Arcutis Biotherapeutics, Inc. owes $0.55 for every $1 it owns (moderate), higher than 60% of Healthcare companies in United States.
Does Arcutis Biotherapeutics, Inc. pay a dividend?
No. Arcutis Biotherapeutics, Inc. does not currently pay a dividend.
Is Arcutis Biotherapeutics, Inc.'s revenue growing?
Revenue rose 91% in the year to Dec 2025, and grew 367% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.